Botulinum Toxin (BTX)
The progress of the society, has taken human life higher, allowing simultaneously the achievement of a better quality of existence, with greater interest for healthy habits and aesthetics. The actual rhythm of life more bound to the immediate result, with minimally invasive interventions tendencies, and as outpatient if possible, so as not to interfere in people’s routine; has increased the popularity of aesthetic procedures worldwide. In this setting, botulinum toxin applications developed exponentially.
The medical use of BTX began in the 1950s, although it was not until 1973 that the first study demonstrating therapeutic value was published. In 1979 the FDA granted limited approval to use of BTX-A for strabismus and, in 1985 this was expanded to include blepharospasm. In 2003 it was approved for the treatment of glabellar rhytides.
Since then BTX has revolutionized the world of cosmetic procedures. Through selective chemical denervation of facial musculature, physicians have been able to treat hiperdynamic rhytides, improve wrinkling and change facial expression.
Several controversial aspects have not been well clarified though, like the possibility of resistance to the toxin, the off-label applications, chronic use and muscular atrophy, the different possible dilutions and the potency and efficacy of the different products available in the market. The former mainly because of lack of support from the pharmaceutical companies that are not willing to reveal the controversial topics.